LIVONIA - Digital Insulin enhancement company, Hygieia, has cut a three-year deal with Blue Cross Blue Shield of Michigan to make its Nav Insulin Guidance Service available at no cost and with no co-pays to BCBSM members with Type 2 diabetes, starting with at-risk populations in Southeast Michigan. Financial terms were not disclosed. The agreement
ANN ARBOR - Genomenon has struck a co-marketing agreement with Fluidigm Corp. to offer evidence-based genomic panel design services for translational and clinical disease research. Through the Fluidigm-Genomenon joint panel design services offering, researchers will be able to accelerate the design of disease-specific next-generation sequencing, genotyping, and real-time PCR panels for use with highly efficient
GRAND RAPIDS — Spectrum Health has committed $7.5 million to a new Chicago-based venture capital fund that backs emerging heath care technologies. The commitment to invest $2.5 million annually over three years into 7wire Ventures’ Connected Consumer Health Fund comes from Spectrum Health Ventures LLC, the $100 million venture capital fund the health system formed in early 2017. By investing
ANN ARBOR — Pharma startup Esperion Therapeutics announced this week the appointment of Jay P. Shepard as a Class III Director, with a term expiring at the 2019 annual meeting of stockholders. “Jay’s experience supporting the launch and commercialization of biopharmaceutical products will be invaluable as we advance the bempedoic acid product franchise through the
ANN ARBOR — Esperion Therapeutics Inc. announced positive top-line results from the third of five pivotal Phase 3 studies expected to be reported this year to evaluate the efficacy in lowering so-called bad cholesterol. The tests were done on Esperion's, lead drug candidate, bempedoic acid, at a dose of 180 milligrams, vs. placebo in high-risk patients
ANN ARBOR - Great Lakes Health Connect is collaborating with the University of Michigan Acute Care Research Unit in expanding its real-time System for Opioid Overdose Surveillance. The pilot project began in Washtenaw County for its first year, and is now expanding to up to five more. Researchers hope to gain a better understanding of
ANN ARBOR - Zomedica Pharmaceuticals Corp has entered into an agreement with Seraph Biosciences to bring human diagnostic technology to veterinarians. Under the terms of this agreement, Zomedica will have exclusive global veterinary industry rights to develop and market a novel pathogen detection system in the form of an innovative point-of-care diagnostic instrument, beginning with
ANN ARBOR—A new, stable artificial photosynthesis device doubles the efficiency of harnessing sunlight to break apart both fresh and salt water, generating hydrogen that can then be used in fuel cells. The device could also be reconfigured to turn carbon dioxide back into fuel. Hydrogen is the cleanest-burning fuel, with water as its only emission.
ANN ARBOR — NanoBio Corp., a clinical-stage biopharmaceutical company, announced that it has changed its corporate name to BlueWillow Biologics in conjunction with the closing of a $10 million Series A financing. The company’s new name reflects its evolution to a vaccines-focused company, and commitment to advancing its novel intranasal technology to develop new vaccines
ANN ARBOR — Kraig Biocraft Laboratories Inc., a biotech and advanced materials developer, announced it has been issued its Enterprise Registration Certificate required to begin its operations in Vietnam. Kraig is developing genetically engineered silkworms that spin silk that has some of the strength characteristics of spiderwebs — so-called “spider silk.” “These licenses to operate
